The US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with NSCLC (non-small cell lung cancer). This approval has been based on the…
Everything about lung cancer is here.
The US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with NSCLC (non-small cell lung cancer). This approval has been based on the…